Gapping up
In reaction to earnings/guidance:
- LDI +5.8%, AKTS +2.8%, ENBL +2%
Other news:
- BTX +37.2% (enters into purchase agreement with Lincoln Park Capital wherein co may sell $20 mln of shares to Lincoln Park)
- OCGN +11.5% (reports on studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2)
- AMPH +7.7% (receives FDA approval for morphine sulfate injection - Pump-Jet Prefilled Syringe System)
- LTRN +5.9% (entered into a research and development collaboration with Actuate Therapeutics)
- GILT +5.4% (enters strategic agreement valued at tens of millions of dollars with a large government corporation in Asia Pacific)
- CABA +5% (reports acute safety data from the first dose cohort in DesCAARTes trial)
- GNFT +4.9% (launches NASHnext)
- ADVM +4.6% (Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 202)
- GENI +4.3% (announces that it has agreed to acquire FanHub Media Holdings Pty Ltd )
- FOLD +4.1% (reports successful pre-BLA meeting with FDA for AT-GAA)
- PROG +3.2% (presents new data from Preecludia preeclampsia rule-out test verification study)
- MRNA +3.2% (receives Emergency Use Listing by the WHO for its COVID-19 vaccine; announces supply agreement with Gavi for up to 500 million doses of COVID-19 vaccine Moderna for COVAX to help end COVID-19 pandemic in lowest income countries)
- AVRO +2.7% (provided an update on its regulatory plans for AVR-RD-01, the first investigational lentiviral gene therapy for Fabry disease)
- TLRY +2.5% (Tilray and Aphria (APHA) announced the completion of the previously announced business combination)
- LI +2.3% (April deliveries)
- SIVB +1.9% (reiterates that it will not increase purchase price in transaction with Boston Private Financial (BPFH))
- GMTX +1.8% (Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting)
- GME +1.6% (expands North American fulfillment network through its entry into a lease of a 700,000 square foot fulfillment center in York, Pennsylvania)
- SABR +1.5% (files for common and preferred stock offering by company or selling shareholders)
- XPEV +1.3% (April deliveries)
- NVS +1.1% (reports Phase III Beovu data met primary endpoints)
- LH +1% (to acquire select operating assets and intellectual property from Myriad Genetics' (MYGN) autoimmune business unit, including the Vectra rheumatoid arthritis assay) .
Analyst comments:
- PTEN +5% (upgraded to Overweight from Equal Weight at Barclays)
- CVNA +3.2% (upgraded to Buy from Neutral at BofA Securities)
- BKR +2.8% (upgraded to Overweight from Equal Weight at Barclays)
- HAL +2.4% (upgraded to Overweight from Equal Weight at Barclays)
- ESRT +2.1% (upgraded to Outperform from Underperform at Evercore ISI)
- USPH +1.8% (upgraded to Buy from Hold at Jefferies)
- DKNG +1.4% (upgraded to Outperform from Market Perform at Cowen)
- WELL +1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)